1. Home
  2. Products
  3. Bone & Mineral Metabolism
  4. IDKmonitor® Infliximab Total ADA ELISA (Health Canada)

IDKmonitor® Infliximab Total ADA ELISA (Health Canada)


Available with Lead Time!

Method: ELISA
Sample Type (Matrix): Serum, EDTA Plasma
Sample Volume: 25 µl
Species: Human
Incubation time: 3h
Size: 96 wells
Regulatory Status: Health Canada Licensed. Not for sale in U.S.
Kit Manual: Download

The IDKmonitor® Infliximab Total ADA ELISA is intended for the determination of human antibodies against TNFα blocker infliximab (e.g. REMICADE®) in the presence of infliximab in EDTA plasma and serum.

Health Canada Licensed. For Laboratory Professional Use Only.

This assay allows a reliable determination of ADA even in the presence of infliximab; therefore, it is ideal for therapeutic drug monitoring when a measurable infliximab concentration is expected. For example, shortly after the last infusion.

In combination with the drug level determination, the IDKmonitor® Infliximab Total ADA ELISA can help physicians monitor and optimize therapy early on.

Chronic inflammatory diseases like Crohn’s disease, ulcerative colitis, or rheumatoid arthritis are often treated with anti-TNFα antibodies, which directly target the underlying inflammatory processes.

The clinical efficacy of an anti-TNFα therapy correlates with the trough level of the therapeutic antibody, the drug level just before the next application of the anti-TNFα antibody. Several factors influence the trough level, among them dosage and frequency of anti-TNFα blocker infusion, disease activity, individual pharmacokinetics, and immune reaction (formation of anti-drug antibodies, ADA). It is thought that ADA functionally neutralizes the therapeutic antibodies or induces their rapid elimination. Consequences of ADA formation can be therapy failure and allergic reactions during anti-TNFα antibody application.

Browse our other IDKmonitor® Infliximab ELISAs.

Test Principle of the IDKmonitor® Infliximab Total ADA ELISA

The IDKmonitor® Infliximab Total ADA ELISA is used for the determination of antibodies against TNFα-Blocker infliximab (e. g. REMICADE®).

During sample preparation, the anti-drug antibodies (ADA) are separated from the therapeutic antibody in order to acquire free ADA. By adding the conjugate (peroxidase-labeled therapeutic antibody) and the tracer (biotinylated therapeutic antibody), the unmarked therapeutic antibodies are replaced and the marked antibodies can form a complex with the ADA. This complex binds via biotin to the streptavidin-coated microtiter plate. It is detected via the peroxidase conjugate with the peroxidase converting the substrate TMB to a blue product.

The enzymatic reaction is stopped by adding an acidic solution. The samples convert from blue to yellow. The color change should be measured in a photometer at 450 nm. The interpretation is made using the cut-off control.


Additional information

Weight35.5 oz
Dimensions6.5 × 10 × 4.5 in
Social media & sharing icons powered by UltimatelySocial

Become an IDK Insider!

Join our mailing list to receive the latest news and updates from Immundiagnostik, Inc.


You have Successfully Subscribed!